Immuneering (NASDAQ:IMRX) Rating Increased to Strong-Buy at Chardan Capital

Immuneering (NASDAQ:IMRX) was upgraded by stock analysts at Chardan Capital to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Several other equities research analysts have also recently commented on IMRX. Oppenheimer reissued an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st. Needham & Company LLC raised their price objective on Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a report on Monday, July 20th. Wall Street Zen downgraded Immuneering from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research note on Wednesday, June 24th. Finally, Cantor Fitzgerald began coverage on shares of Immuneering in a research note on Wednesday, July 8th. They issued an “overweight” rating and a $17.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $17.57.

Immuneering Price Performance

IMRX stock opened at $4.39 on Monday. The stock has a market capitalization of $284.03 million, a P/E ratio of -3.75 and a beta of 0.43. The business has a 50-day moving average of $4.60 and a 200-day moving average of $4.98. Immuneering has a fifty-two week low of $2.90 and a fifty-two week high of $10.08.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01). The company had revenue of $0.36 million during the quarter. Equities analysts expect that Immuneering will post -1.09 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd bought a new stake in shares of Immuneering during the fourth quarter worth approximately $33,000. Levin Capital Strategies L.P. acquired a new position in shares of Immuneering in the first quarter valued at approximately $53,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Immuneering during the third quarter worth approximately $70,000. SummitTX Capital L.P. bought a new position in shares of Immuneering during the fourth quarter worth approximately $69,000. Finally, Ausdal Financial Partners Inc. acquired a new stake in Immuneering during the 4th quarter worth approximately $72,000. 67.65% of the stock is owned by institutional investors.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.